Intevac Announces Third Quarter 2014 Financial Results
Mon, October 27 2014
“We are pleased to report another record quarter for our Photonics
business, both in terms of revenue and operating profit, and expect to
achieve growth exceeding 30% this year as compared to 2013," commented
“Our hard drive equipment business continues to be negatively impacted by excess media capacity and a slower than projected rate of increase in exabyte shipments this year. However, we are encouraged by recent improvements in industry fundamentals, with PC demand stabilizing and HDD units exceeding estimates for the third quarter.”
($ Millions, except per share amounts) | Q3 2014 | Q3 2013 | ||||||||||||||
GAAP Results | Non-GAAP Results | GAAP Results | Non-GAAP Results | |||||||||||||
Net Revenues | $ | 14.8 | $ | 14.8 | $ | 19.1 | $ | 19.1 | ||||||||
Operating Loss | $ | (4.1 | ) | $ | (4.2 | ) | $ | (3.0 | ) | $ | (2.8 | ) | ||||
Net Loss | $ | (3.6 | ) | $ | (3.6 | ) | $ | (2.7 | ) | $ | (2.6 | ) | ||||
Net Loss per Share | $ | (0.15 | ) | $ | (0.15 | ) | $ | (0.11 | ) | $ | (0.11 | ) | ||||
|
Nine Months Ended | Nine Months Ended | ||||||||||||||
|
|
|||||||||||||||
GAAP Results | Non-GAAP Results | GAAP Results | Non-GAAP Results | |||||||||||||
Net Revenues | $ | 46.5 | $ | 46.5 | $ | 49.1 | $ | 49.1 | ||||||||
Operating Loss | $ | (14.1 | ) | $ | (13.7 | ) | $ | (19.0 | ) | $ | (18.1 | ) | ||||
Net Loss | $ | (13.1 | ) | $ | (12.8 | ) | $ | (17.4 | ) | $ | (16.5 | ) | ||||
Net Loss per Share | $ | (0.55 | ) | $ | (0.54 | ) | $ | (0.73 | ) | $ | (0.69 | ) | ||||
Intevac’s non-GAAP adjusted results exclude the impact of the following, where applicable: (1) changes in fair value of contingent consideration liabilities associated with business combinations; (2) restructuring charges; and (3) gains or losses on sales of product lines and technology assets. A reconciliation of the GAAP and non-GAAP adjusted results is provided in the financial table included in this release. See also “Use of Non-GAAP Financial Measures” section.
Third Quarter 2014 Summary
The net loss for the quarter was
Revenues were
Equipment gross margin was (9.5)% compared to 39.7% in the third quarter of 2013 and 8.3% in the second quarter of 2014. Equipment margins in the third quarter of 2014 reflected a lower revenue volume and lower factory absorption.
Photonics gross margin was 45.1% compared to 30.3% in the third quarter of 2013 and 44.7% in the second quarter of 2014. The improvement from the third quarter of 2013 was driven by higher margin product revenue and higher margins on technology development programs. Consolidated gross margin was 32.6%, compared to 36.1% in the third quarter of 2013 and 35.4% in the second quarter of 2014.
Operating expenses were
Order backlog totaled
The company ended the quarter with
The company repurchased 868,000 shares of common stock for a total of
First Nine Months 2014 Summary
The net loss was
Revenues were
Equipment gross margin was 12.3%, compared to 27.4% in the first nine months of 2013, primarily due to the lower level of revenue from upgrades and lower factory absorption. Fiscal 2013 margins reflected a refurbishment provision for a solar evaluation system, and the lower system margin on the first solar implant ENERGi system recognized for revenue. Photonics gross margin was 42.4% compared to 30.8% in the first nine months of 2013, reflecting higher margin product revenue, improved sensor yields, and higher margins on technology development programs. Consolidated gross margin was 31.9%, compared to 29.0% in the first nine months of 2013.
Operating expenses were
Use of Non-GAAP Financial Measures
Management uses non-GAAP results to evaluate the company’s operating and
financial performance in light of business objectives and for planning
purposes. These measures are not in accordance with GAAP and may differ
from non-GAAP methods of accounting and reporting used by other
companies.
Conference Call Information
The company will discuss its financial results and outlook in a conference call today at 1:30 p.m. PDT (4:30 p.m. EDT). To participate in the teleconference, please call toll-free (877) 334-0811 prior to the start time. For international callers, the dial-in number is (408) 427-3734. You may also listen live via the Internet at the company's website, www.intevac.com, under the Investors link, or at www.earnings.com. For those unable to attend, these web sites will host an archive of the call. Additionally, a telephone replay of the call will be available for 48 hours beginning today at 7:30 p.m. EDT. You may access the replay by calling (855) 859-2056 or, for international callers, (404) 537-3406, and providing Replay Passcode 17085532.
About
In our Equipment business, we are a leader in the design and development of high-productivity, thin film processing systems. Our production-proven platforms are designed for high-volume manufacturing of substrates with precise thin film properties.
In our Photonics business, we are a recognized leading developer of advanced high-sensitivity digital sensors, cameras and systems that primarily serve the defense industry. We are the sole-source provider of integrated digital imaging systems for most U.S. military night vision programs.
For more information call 408-986-9888, or visit the company's website at www.intevac.com.
200 Lean® is a registered trademark and
Safe Harbor Statement
This press release includes statements that constitute “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995 (the “Reform Act”).
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, in thousands, except per share amounts) |
||||||||||||||||
Three months ended | Nine months ended | |||||||||||||||
|
|
|
|
|||||||||||||
Net revenues | ||||||||||||||||
Equipment | $ | 3,375 | $ | 11,760 | $ | 16,184 | $ | 26,293 | ||||||||
Photonics | 11,382 | 7,355 | 30,304 | 22,788 | ||||||||||||
Total net revenues | 14,757 | 19,115 | 46,488 | 49,081 | ||||||||||||
Gross profit | 4,815 | 6,895 | 14,836 | 14,237 | ||||||||||||
Gross margin | ||||||||||||||||
Equipment | (9.5 | )% | 39.7 | % | 12.3 | % | 27.4 | % | ||||||||
Photonics | 45.1 | % | 30.3 | % | 42.4 | % | 30.8 | % | ||||||||
Consolidated | 32.6 | % | 36.1 | % | 31.9 | % | 29.0 | % | ||||||||
Operating expenses | ||||||||||||||||
Research and development | 3,986 | 4,250 | 12,817 | 16,192 | ||||||||||||
Selling, general and administrative | 4,991 | 5,442 | 16,055 | 16,858 | ||||||||||||
Acquisition-related1 | (78 | ) | 185 | 19 | (24 | ) | ||||||||||
Total operating expenses | 8,899 | 9,877 | 28,891 | 33,026 | ||||||||||||
Loss on divestiture2 | — | — | — | (208 | ) | |||||||||||
Total operating loss | (4,084 | ) | (2,982 | ) | (14,055 | ) | (18,997 | ) | ||||||||
Operating income (loss) | ||||||||||||||||
Equipment | (5,872 | ) | (1,423 | ) | (15,681 | ) | (14,607 | ) | ||||||||
Photonics | 3,120 | 192 | 6,595 | 254 | ||||||||||||
Corporate1,2 | (1,332 | ) | (1,751 | ) | (4,969 | ) | (4,644 | ) | ||||||||
Total operating income (loss) | (4,084 | ) | (2,982 | ) | (14,055 | ) | (18,997 | ) | ||||||||
Interest and other income (expense) | 113 | 220 | 306 | 392 | ||||||||||||
Loss before income taxes | (3,971 | ) | (2,762 | ) | (13,749 | ) | (18,605 | ) | ||||||||
Benefit for income taxes | 412 | 17 | 662 | 1,184 | ||||||||||||
Net loss | $ | (3,559 | ) | $ | (2,745 | ) | $ | (13,087 | ) | $ | (17,421 | ) | ||||
Loss per share | ||||||||||||||||
Basic and Diluted | $ | (0.15 | ) | $ | (0.11 | ) | $ | (0.55 | ) | $ | (0.73 | ) | ||||
Weighted average common shares outstanding | ||||||||||||||||
Basic and Diluted | 23,657 | 23,931 | 23,814 | 23,793 |
1Results for all periods presented include changes in fair value of contingent consideration obligations associated with the Solar Implant Technology (SIT) acquisition in 2010.
2Nine months ended
CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except par value) |
||||||||
|
|
|||||||
(Unaudited) | (see Note) | |||||||
ASSETS | ||||||||
Current assets | ||||||||
Cash, cash equivalents and short-term investments | $ | 54,487 | $ | 69,096 | ||||
Accounts receivable, net | 9,399 | 15,037 | ||||||
Inventories | 23,109 | 22,762 | ||||||
Prepaid expenses and other current assets | 1,791 | 1,237 | ||||||
Total current assets | 88,786 | 108,132 | ||||||
Long-term investments | 16,253 | 12,318 | ||||||
Restricted cash | 1,000 | — | ||||||
Property, plant and equipment, net | 12,438 | 12,945 | ||||||
Deferred income tax assets | 9,918 | 9,502 | ||||||
Intangible assets, net | 4,200 | 4,902 | ||||||
Other long-term assets | 54 | 477 | ||||||
Total assets | $ | 132,649 | $ | 148,276 | ||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
Current liabilities | ||||||||
Accounts payable | $ | 4,601 | $ | 4,011 | ||||
Accrued payroll and related liabilities | 4,327 | 5,034 | ||||||
Deferred income tax liabilities | 939 |
|
939 |
|||||
Other accrued liabilities | 6,258 | 3,263 | ||||||
Customer advances | 1,798 | 3,743 | ||||||
Total current liabilities | 17,923 | 16,990 | ||||||
Other long-term liabilities | 1,821 | 1,715 | ||||||
Stockholders’ equity | ||||||||
Common stock ( |
23 | 24 | ||||||
Additional paid in capital | 160,282 | 156,359 | ||||||
Treasury stock, at cost | (9,163 | ) | (1,688 | ) | ||||
Accumulated other comprehensive income | 699 | 725 | ||||||
Accumulated deficit | (38,936 | ) | (25,849 | ) | ||||
Total stockholders’ equity | 112,905 | 129,571 | ||||||
Total liabilities and stockholders’ equity | $ | 132,649 | $ | 148,276 | ||||
Note: Amounts as of
RECONCILIATION OF GAAP TO NON-GAAP RESULTS (Unaudited, in thousands, except per share amounts) |
||||||||||||||||
Three months ended |
|
Nine months ended |
||||||||||||||
|
|
|
|
|||||||||||||
Non-GAAP Loss from Operations | ||||||||||||||||
Reported operating loss (GAAP basis) | $ | (4,084 | ) | $ | (2,982 | ) | $ | (14,055 | ) | $ | (18,997 | ) | ||||
Change in fair value of contingent consideration obligations1 | (78 | ) | 185 | 19 | (24 | ) | ||||||||||
Restructuring charges2 | — | — | 288 | 742 | ||||||||||||
Loss on sale of Raman spectroscopy product line3 | — | — | — | 208 | ||||||||||||
Non-GAAP Operating Loss | $ | (4,162 | ) | $ | (2,797 | ) | $ | (13,748 | ) | $ | (18,071 | ) | ||||
Non-GAAP Net Loss | ||||||||||||||||
Reported net loss (GAAP basis) | $ | (3,559 | ) | $ | (2,745 | ) | $ | (13,087 | ) | $ | (17,421 | ) | ||||
Change in fair value of contingent consideration obligations1 | (78 | ) | 185 | 19 | (24 | ) | ||||||||||
Restructuring charges2 | — | — | 288 | 742 | ||||||||||||
Loss on sale of Raman spectroscopy product line3 | — | — | — | 208 | ||||||||||||
Income tax effect of non-GAAP adjustments4 | — | — | — | (42 | ) | |||||||||||
Non-GAAP Net Loss | $ | (3,637 | ) | $ | (2,560 | ) | $ | (12,780 | ) | $ | (16,537 | ) | ||||
Non-GAAP Loss Per Diluted Share | ||||||||||||||||
Reported loss per diluted share (GAAP basis) | $ | (0.15 | ) | $ | (0.11 | ) | $ | (0.55 | ) | $ | (0.73 | ) | ||||
Change in fair value of contingent consideration obligations1 | — | 0.01 | — | — | ||||||||||||
Restructuring charges2 | — | — | 0.01 | 0.03 | ||||||||||||
Loss on sale of Raman spectroscopy product line3 | — | — | — | 0.01 | ||||||||||||
Non-GAAP Loss Per Diluted Share | $ | (0.15 | ) | $ | (0.11 | ) | $ | (0.54 | ) | $ | (0.69 | ) | ||||
Weighted average number of diluted shares | 23,657 | 23,931 | 23,814 | 23,793 | ||||||||||||
1Results for all periods presented include changes in fair value of contingent consideration obligations associated with the Solar Implant Technology (SIT) acquisition in 2010.
2Results for all periods presented include severance and other employee-related costs related to various restructuring programs.
3The nine months ended
4The amount represents the estimated income tax effect of the non-GAAP adjustments. The Company calculated the tax effect of non-GAAP adjustments by applying an applicable estimated jurisdictional tax rate to each specific non-GAAP item.
Chief Financial
Officer
Investor Relations
Source: